Public Disclosures

DateTitleReporter
21.July.2021
Acquisition of patent rights for ‘Method for preparing antibody through regulation of sugar content of antibody’ in EuropePrestige BioPharma Limited
18.June.2021
Approval for PBP1510 clinical trial (Phase 1/2a) in FrancePrestige BioPharma Limited
15.June.2021
Confirmed list of shareholders & voting rights as of 30/June/2021 for shareholders’ meetingPrestige BioPharma Limited
28.May.2021
Decision to make an equity investment on PBP Korea Prestige BioPharma Limited
28.May.2021
Decision to make a cash loan to PBP KoreaPrestige BioPharma Limited
28.May.2021
Quarterly report (FY2021, Q3) Prestige BioPharma Limited
26.May.2021
Acquisition of patent rights for ‘Antibody specifically binding to PAUF and use thereof’ in USAPrestige BioPharma Limited
24.Feb.2021
Change of KOSPI stock namePrestige BioPharma Limited
18.Feb.2021
Report on status of specific securities owned by executive officersBang Kyuho
16.Feb.2021
Report on stocks held in bulk Octava Fund Limited
16.Feb.2021
Report on status of specific securities owned by executive officersOctava Fund Limited
16.Feb.2021
Report on changes in equity shares of the largest shareholderPrestige BioPharma Limited
15.Feb.2021
Report on status of specific securities owned by executive officersJeon Kyunghee
15.Feb.2021
Report on status of specific securities owned by executive officersMichael Jinwoo Kim
15.Feb.2021
Report on status of specific securities owned by executive officersPark Soyeon
15.Feb.2021
Report on status of specific securities owned by executive officersMayson Partners
15.Feb.2021
Report on stocks held in bulk Mayson Partners
28.Jan.2021
Report on results of issuance of securitiesPrestige BioPharma Limited
22.Jan.2021
ProspectusPrestige BioPharma Limited
22.Jan.2021
Securities registration statement (IPO)Prestige BioPharma Limited